
2023-04
喜讯 | 博生吉医药TAA06注射液顺利完成I期临床试验的首例患者回输
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co. Ltd is a biotech company focusing on developing leading-edge cellular therapeutics. The company is committed to developing CAR-related therapeutic and analytical antibodies, novel CAR- products, and allogeneic cellular therapies. The company has developed a comprehensive pipeline of products and a world-leading allogeneic off-the-shelf UCAR-Vδ1 T-cell R&D platform.
PersonGen.Anke Cellular Therapeutics Co., Ltd.
PersonGen-Anke Cellular Therapeutics Co., Ltd. is a subsidiary company and the manufacturing base of PersonGen BioTherapeutics. The company is equipped with the global-leading fully-automated, closed manufacturing system for cellular therapeutics. It also has the most advanced facilities for the manufacturing of clinical-grade DNA plasmids and lentiviruses. The company has developed fully validated manufacturing processes of CAR-T, allogeneic γδT and UCAR-γδT products.
Read More
PersonGen BioTherapeutics is one of the first company in China focusing on the development of CAR-T and other cellular immunotherapies.
We are driven by our values “Care for People, Cure Every Patient”, and is committed to being the world leader on developing allogeneic cellular therapies against tumors and autoimmunity diseases.
中国苏州,2023年4月17日——博生吉医药科技,一家以突破性细胞新药研发为主要业务的国家高新技术企业,今日公告,公司自主研...
近日,博生吉医药科技(苏州)有限公司携手国内多家顶尖血液病研究中心,于国际权威学术会议EHA 2025上,以壁报(PS1369)形式重磅公布...
2025年5月9日-10日,由动脉网主办的 “2025 VBEF 未来医疗医药百强展会” 在苏州国际博览中心盛大举行。展会期间,备受瞩目的 ...
博生吉医药集团开发的、基于Vδ1T细胞的靶向CD19的通用现货型嵌合抗原受体(CAR)-T细胞注射液(研发代号:UTAA09注射液)临床试验...
2025年4月2日,由谈思生物主办的CGT Asia 2025第八届亚洲细胞与基因治疗创新峰会在上海隆重开幕。同时“CGT Awards”2...
Conceptual Pilot Study, Patient Recruitment
Read More